Literature DB >> 10619715

Homozygosity for a nonsense mutation in the alpha-tropomyosin slow gene TPM3 in a patient with severe infantile nemaline myopathy.

P Tan1, J Briner, E Boltshauser, M R Davis, S D Wilton, K North, C Wallgren-Pettersson, N G Laing.   

Abstract

The nemaline myopathies are muscle disorders of variable severity and age of onset, with characteristic nemaline bodies in the sarcoplasm. Genes for dominant (NEM1) and recessive (NEM2A) nemaline myopathy have been localised to chromosomes one and two, respectively. A missense mutation in the alpha-tropomyosin gene (TPM3) has been associated with NEM1 in one family. Probands from 76 other nemaline myopathy families have now been screened for TPM3 mutations. One proband, who was not noted to have any weakness neonatally, but who died at 21 months of age, was shown to be homozygous for a single strand conformation polymorphism (SSCP) in skeletal-muscle-specific exon 1 of TPM3. Sequencing revealed homozygosity for a nonsense mutation at codon 31 (CAG to TAG). The patient should have no functioning alpha-tropomyosin slow protein. The nemaline bodies in this patient were exclusively in type one fibres, consistent with the expression of TPM3 only in type one fibres.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619715     DOI: 10.1016/s0960-8966(99)00053-x

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  21 in total

1.  Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene.

Authors:  Sylvia L Anderson; Josef Ekstein; Mary C Donnelly; Erin M Keefe; Nicole R Toto; Lauretta A LeVoci; Berish Y Rubin
Journal:  Hum Genet       Date:  2004-06-23       Impact factor: 4.132

2.  Clinical utility gene card for: nemaline myopathy.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2012-04-18       Impact factor: 4.246

3.  Localization of the binding interface between leiomodin-2 and α-tropomyosin.

Authors:  Mert Colpan; Dmitri Tolkatchev; Samantha Grover; Gregory L Helms; John R Cort; Natalia Moroz; Alla S Kostyukova
Journal:  Biochim Biophys Acta       Date:  2016-02-09

4.  Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1).

Authors:  Nigel G Laing; Danielle E Dye; Carina Wallgren-Pettersson; Gabriele Richard; Nicole Monnier; Suzanne Lillis; Thomas L Winder; Hanns Lochmüller; Claudio Graziano; Stella Mitrani-Rosenbaum; Darren Twomey; John C Sparrow; Alan H Beggs; Kristen J Nowak
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

5.  Clinical utility gene card for: Nemaline myopathy - update 2015.

Authors:  Kristen J Nowak; Mark R Davis; Carina Wallgren-Pettersson; Phillipa J Lamont; Nigel G Laing
Journal:  Eur J Hum Genet       Date:  2015-02-25       Impact factor: 4.246

6.  Alteration of tropomyosin function and folding by a nemaline myopathy-causing mutation.

Authors:  J Moraczewska; N J Greenfield; Y Liu; S E Hitchcock-DeGregori
Journal:  Biophys J       Date:  2000-12       Impact factor: 4.033

7.  Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber hypotrophy in congenital fiber type disproportion.

Authors:  Michael W Lawlor; Elizabeth T Dechene; Emily Roumm; Amelia S Geggel; Behzad Moghadaszadeh; Alan H Beggs
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

8.  Skeletal muscle myopathy mutations at the actin tropomyosin interface that cause gain- or loss-of-function.

Authors:  Massimiliano Memo; Steven Marston
Journal:  J Muscle Res Cell Motil       Date:  2013-05-30       Impact factor: 2.698

9.  Myofilament lattice structure in presence of a skeletal myopathy-related tropomyosin mutation.

Authors:  Julien Ochala; Hiroyuki Iwamoto
Journal:  J Muscle Res Cell Motil       Date:  2013-05-18       Impact factor: 2.698

Review 10.  Thin filament proteins mutations associated with skeletal myopathies: defective regulation of muscle contraction.

Authors:  Julien Ochala
Journal:  J Mol Med (Berl)       Date:  2008-06-24       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.